Authors
Latest:
Independent Pharmacy: A Day in the LifeSimon Murray, MD, recently spent the day with Chris Castagna, RPh, an independent pharmacist.
Latest:
Opinion: The Truth About ARCOS and the Opioid EpidemicThe DEA had access to information about where opioids were being sold, but didn’t act on it. Why?
Latest:
New Drug Review: Tafamidis Meglumine for CardiomyopathyApproved in May 2019, granted to FoldRx, a subsidiary of Pfizer.
Latest:
New Drug Review: Tafamidis Meglumine for CardiomyopathyApproved in May 2019, granted to FoldRx, a subsidiary of Pfizer.
Latest:
Toxicity Management Crucial When Combining Novel AgentsOff-label drug combinations are increasingly being used in cancer treatments, but there is the potential for overlapping or additive toxicities, explained a speaker at the 2023 HOPA Annual Conference.
Latest:
Pharmacists Can Help Patients as Signs of Normalcy ReturnAlthough COVID-19 remains a real threat, it seems we are now progressing toward a return to normalcy thanks to the widespread availability of vaccines and tireless efforts of our health care workers.
Latest:
Build a Successful Hospital Pharmacy Analytics ProgramLeverage internal partnerships and demonstrate the value of data
Latest:
Can Pharmacists be Blamed as Co-Conspirators in the Opioid Crisis?What the law says about pharmacists’ role in the opioid crisis-and how to protect yourself.
Latest:
New Measles and Rubella Vaccine Found to be Safe and EffectiveMebella is another weapon in the global fight to eradicate these diseases.
Latest:
All Ages Need Education on SunscreenData from one study showed younger women more likely to use sunscreen than older adults.
Latest:
Relying on Your Distributor Through Natural DisastersThe critical role of distributors amid natural disasters, and strategies to protect and maintain the pharma supply chain
Latest:
The Impact of Patents and Exclusivities on FDA’s Approval of Generic DrugsWhat are some of the factors affecting whether a brand-name drug has generic competition?
Latest:
Lefamulin (Xenleta) for Community Acquired Bacterial PneumoniaLefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Latest:
Here’s a Tip: More Money Is the SolutionIn many industries, tipping is the norm. Pharmacists would just like to receive payment for services rendered.
Latest:
Sunosi for Excessive Sleepiness in Adults with Narcolepsy or Obstructive Sleep ApneaSolriamfetol (Sunosi, Jazz Pharmaceuticals) to treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea was approved on March 20, 2019.
Latest:
Q&A: PBM Legislation “Highly Likely” to Pass This YearFollowing the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.
Latest:
Debunking 4 Common Myths About the FluIt’s never too far into flu season to educate patients.
Latest:
Cannabis Consulting: Are You Ready?Most pharmacists are moderately to not-at-all comfortable answering patient questions about cannabis. That needs to change.
Latest:
Communicating with Patients in the Time of COVID-19Pharmacies, just as expected, have showed up in meaningful ways to support their communities.
Latest:
Lumateprone Tosylate Approved for SchizophreniaThe FDA has approved lumateperone tosylate (Caplyta™, Intra-Cellular Therapies) for treatment of schizophrenia in adults.
Latest:
Literature Evaluation: More Than Just the GuidelinesBuilding literature evaluation skills is an essential teaching component during all stages of pharmacy education
Latest:
Entrectinib for ROS1-Positive NSCLC and NTRK-Positive Solid TumorsIn August 2019, the FDA approved entrectinib for treatment of adult patients with metastatic non-small cell lung cancer that is ROS1-positive.
Latest:
Darolutamide for Non-Metastatic Castration-Resistant Prostate CancerIn July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
Latest:
Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Unresectable or Metastatic Breast CancerFam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) is indicated for treating adults with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2–based regimens in the setting of metastasis.
Latest:
Evidence-Based Treatment for Pediatric Migraine PreventionMigraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.
Latest:
Evidence-Based Treatment for Pediatric Migraine PreventionMigraine is one of the most common neurologic disorders in children and adolescents with a prevalence of 7.7%.
Latest:
Drug Interaction Concerns for Potential COVID-19 TreatmentsA close look at their potential to interact with other medications is required to limit the risk of adverse outcomes for patients.
Latest:
The Need for Patient-Specific Medication Optimization SystemsMedication decision support tools focused on individual patients can help pharmacists effectively analyze risk of unintended harm, identify and assess potential interventions, and facilitate longitudinal care.
Latest:
Smell Disturbances in the Era of COVID-19Some patients affected by COVID-19 may be concerned about hyposmia (reduced ability to smell) or anosmia (loss of smell) that they experience after contracting the virus.
